Cart
sales@molnova.com
GW779439X
CAS No. 551919-98-3
GW779439X( —— )
Catalog No. M24539 CAS No. 551919-98-3
GW779439X is an inhibitor of CDK.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 126 | In Stock |
|
| 2MG | 75 | In Stock |
|
| 5MG | 116 | In Stock |
|
| 10MG | 188 | In Stock |
|
| 25MG | 426 | In Stock |
|
| 50MG | 612 | In Stock |
|
| 100MG | 872 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGW779439X
-
NoteResearch use only, not for human use.
-
Brief DescriptionGW779439X is an inhibitor of CDK.
-
DescriptionGW779439X is an inhibitor of CDK.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorCDK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number551919-98-3
-
Formula Weight454.45
-
Molecular FormulaC22H21F3N8
-
Purity>98% (HPLC)
-
SolubilityDMSO:10 mM
-
SMILESCN1CCN(CC1)C2=C(C=C(C=C2)NC3=NC=CC(=N3)C4=C5C=CC=NN5N=C4)C(F)(F)F
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Schaenzer A J , Wlodarchak N , Drewry D H , et al. GW779439X and Its Pyrazolopyridazine Derivatives Inhibit the Serine/Threonine Kinase Stk1 and Act As Antibiotic Adjuvants against β-Lactam-Resistant Staphylococcus aureus[J]. other, 2018, 4(10).
molnova catalog
related products
-
Cdc7 inhibitor 7c
A highly potent, selective and time-dependent Cdc7 kinase inhibitor with IC50 of 0.7 nM with slow dissociation property, with 200-fold and >14,000-fold selectivity over CDK2 and ROCK1, respectively.
-
(R)-CR8
(R)-CR8 is a potent and selective CDK inhibitor.A delayed systemic post-LFP administration at 3 hours of CR8--a potent second-generation cyclin-dependent kinase (CDK) inhibitor.
-
M2I-1
The first small molecule Mad2 inhibitor that targets the binding of Mad2 to Cdc20; equally potent in inhibiting the binding of F-Mbp1 to Mad2.
